Skip to main content

Vutrisiran Dosage

Medically reviewed by Last updated on Feb 23, 2023.

Applies to the following strengths: 25 mg/0.5 mL

Usual Adult Dose for Hereditary Amyloidosis

Recommended dose: 25 mg administered by subcutaneous injection once every 3 months

Use: Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Renal Dose Adjustments

Mild and Moderate Renal Dysfunction: No adjustment recommended.
Severe Renal Dysfunction and End-Stage Renal Disease: Data not available

Liver Dose Adjustments

Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available


US FDA requires a medication guide to assure safe use. For additional information:


Safety and efficacy have not been established in patients younger than 18 years.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:


Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.